✦ LIBER ✦

Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors

✍ Scribed by Peter Kozuch; Paulo M. Hoff; Kenneth Hess; Jennifer Adams; Robert A. Newman; Francis Lee; Richard Pazdur

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 88 KB
Volume: 91
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(20010215)91:4<815::aid-cncr1069>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of gemcitabine and docet

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors

✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

Phase I study of CI-958 in children and

Phase I study of CI-958 in children and adolescents with recurrent solid tumors

✍ Carola A. S. Arndt; Mark D. Krailo; Wen Liu-Mares; Peter M. Anderson; Gregory H. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

BACKGROUND. CI-958 is a synthetic intercalating agent of a new chemical class, the benzopyranoindazoles, with promising preclinical activity. Its mechanism of action is thought to be stabilization of the cleavable complex of DNA with topoisomerase II, as well as DNA helicase blockade. It is thought

A Phase I study of raltitrexed and pacli

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

✍ Everett E. Vokes; Boon C. Goh; Donna Bertucci; Nicholas J. Vogelzang; Sridhar Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 2 views

## BACKGROUND. Raltitrexed is a novel thymidylate synthase inhibitor with single agent activity in colorectal, nonsmall cell lung, and breast carcinomas. The recommended Phase II dose of raltitrexed administered as a single agent is 3 mg/m 2 every 3 weeks. Paclitaxel also has a broad spectrum of a

A phase i study of emetine hydrochloride

A phase i study of emetine hydrochloride (nsc 33669) in solid tumors

✍ Michael J. Mastrangelo; Theodor B. Grage; Robert E. Bellet; Arthur J. Weiss 📂 Article 📅 1973 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 1 views

Phase I clinical trial of weekly combine

Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors

✍ Jacob Lokich 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule. ## METHODS. Patients were accrued in 3-6 patient cohorts to P

Phase II study of daily oral etoposide i

Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors

✍ Needle, Michael N.; Molloy, Patricia T.; Geyer, J. Russell; Herman-Liu, Alisa; B 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 2 views

Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of or